LONDON: Oxford’s Covid-19 vaccine candidate has a better immune response when using a two full dose regimen rather than a full dose followed by a half-dose booster dose, the university said Thursday.
The candidate vaccine, which has been licensed to AstraZeneca, has published the results of an interim late-stage trial showing greater efficacy when half the dose is followed by a full dose, compared to a two full dose regimen, although more work needs to be done to affirm the result.
Details of the Phase I / II clinical trials released Thursday made no reference to the half-dose / full-dose regimen, which Oxford has said was not “planned” but approved by regulators.
The university said it had explored two dosing regimens in the early stages of the trials, a full-dose / full-dose regimen and a full-dose / half-dose regimen, investigated as a possible “dose-sparing” strategy.
“Booster doses of the vaccine have been shown to induce stronger antibody responses than a single dose, and the standard dose / standard dose induces the best response,” the university said in a statement.
The vaccine “stimulates broad antibody and T-cell functions,” he said after publishing more data from phase I / II clinical trials.
The candidate vaccine, which has been licensed to AstraZeneca, has published the results of an interim late-stage trial showing greater efficacy when half the dose is followed by a full dose, compared to a two full dose regimen, although more work needs to be done to affirm the result.
Details of the Phase I / II clinical trials released Thursday made no reference to the half-dose / full-dose regimen, which Oxford has said was not “planned” but approved by regulators.
The university said it had explored two dosing regimens in the early stages of the trials, a full-dose / full-dose regimen and a full-dose / half-dose regimen, investigated as a possible “dose-sparing” strategy.
“Booster doses of the vaccine have been shown to induce stronger antibody responses than a single dose, and the standard dose / standard dose induces the best response,” the university said in a statement.
The vaccine “stimulates broad antibody and T-cell functions,” he said after publishing more data from phase I / II clinical trials.
.
